Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497630 | 0.98 | TSHR (0.38) | TSHRMEN1KMT2APOLBEPHX2 | |
| SCHEMBL577126 | 0.93 | — | — | |
| SCHEMBL498175 | 0.89 | — | — | |
| SCHEMBL27842894 | 0.88 | MEN1 (0.43) | TSHRMEN1KMT2APOLBEPHX2 | |
| SCHEMBL5446086 | 0.83 | DRD4 (0.33) | TSHRPOLBDRD4ALDH1A1NOS1 | |
| SCHEMBL28596584 | 0.81 | DRD4 (0.35) | TSHRPOLBDRD4ALDH1A1NOS1 | |
| SCHEMBL31091562 | 0.81 | DRD4 (0.38) | TSHRMEN1KMT2APOLBDRD4 | |
| SCHEMBL9830249 | 0.79 | DRD4 (0.37) | TSHRMEN1KMT2APOLBDRD4 | |
| SCHEMBL12482758 | 0.79 | MAPK1 (0.36) | TSHRDRD4ALDH1A1NOS1HSD17B10 | |
| SCHEMBL25483361 | 0.79 | ALDH1A1 (0.38) | TSHRPOLBDRD4ALDH1A1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-12-07 | — | — | US | claimed |
| CN-115698021-A | Substituted thiazolopyridines, salts thereof and their use as herbicidal active substances | 拜耳公司 | 2023-02-03 | — | — | CN | claimed |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. | 2021-03-25 | — | — | US | claimed |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-10-29 | — | — | US | claimed |
| US-20180263965-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2018-09-20 | — | — | US | claimed |
| US-9987259-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-06-05 | — | — | US | claimed |
| US-20160166552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-06-16 | — | — | US | claimed |
| US-9271976-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-03-01 | — | — | US | claimed |
| US-20150111901-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOBPHARMACEUTICALS CO LTD (KR) | 2015-04-23 | — | — | US | claimed |
| US-8952165-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-02-10 | — | — | US | claimed |
| US-20130296340-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-11-07 | — | — | US | claimed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | NOVARTIS AG (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20220251152-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| EP-3781563-B1 | HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF | ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2007029035-A2 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-0821675-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033176-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111901-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | TSHR 3361/4885MEN1 1794/4885KMT2A 2767/4885 |
| US-20180263965-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | TSHR 3361/4885MEN1 1794/4885KMT2A 2767/4885 |
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | TSHR 3361/4885MEN1 1794/4885KMT2A 2767/4885 |
| US-20160166552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | TSHR 3361/4885MEN1 1794/4885KMT2A 2767/4885 |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | TSHR 3909/4885MEN1 2977/4885KMT2A 352/4885 |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | HAVCR2, MICA, CD74 | TSHR 1180/4885MEN1 3909/4885KMT2A 499/4885 |
| US-20130296340-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | TSHR 3361/4885MEN1 1794/4885KMT2A 2767/4885 |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | PLPBP, PDXK, PIR | TSHR 3361/4885MEN1 1794/4885KMT2A 2767/4885 |
| US-20220251152-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | RPS27A, PSMG3, PREP | TSHR 3394/4885MEN1 1720/4885KMT2A 3981/4885 |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PNPO | TSHR 3392/4885MEN1 1831/4885KMT2A 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.